Fumio Imamura
Osaka International Cancer Institute · 393 works · 23,063 citations · h-index 55
Top works
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- Induction of in Vitro Tumor Cell Invasion of Cellular Monolayers by Lysophosphatidic Acid or Phospholipase D
- Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years
- Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer
- Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105
- Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection
- Inhibition of in vitro Tumor Cell Invasion by Ginsenoside Rg3
- Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer
- Clinical Efficacy and Safety of Nivolumab: Results of a M ulticenter, Op e n-label, Single-a r m, Japanese Phase II study in Mal i gnant Pleural Meso t helioma (MERIT)
- rho-mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion
- Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
- Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L